Protocol Ledger

NCT07227246 · Phase III · RECRUITING

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Interventional Phase III clinical trial protocol NCT07227246 sponsored by Joseph Broderick, MD in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-06 Enrollment: 350 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07227246
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07227246
Protocol FieldVerified Registry Value
NCT IdentifierNCT07227246
Consolidated Lead SponsorJoseph Broderick, MD
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment350 participants (ESTIMATED)
Registered Start Date2025-05-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI